53,719 XNAS Volume
XNAS 25 Mar, 2025 10:09 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Leonard M.J. Reyno | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 87,100 | 178,909 | - | 0 | Common Stock | |
| Leonard M.J. Reyno | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 130,600 | 130,600 | - | - | Stock Option (Right to Buy) | |
| Leonard M.J. Reyno | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 14 Feb 2025 | 5,145 | 173,764 | - | 3.2 | 16,361 | Common Stock |
| Andrew J. Hirsch | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 14 Feb 2025 | 12,847 | 432,515 | - | 3.2 | 40,853 | Common Stock |
| Andrew J. Hirsch | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 335,300 | 335,300 | - | - | Stock Option (Right to Buy) | |
| Andrew J. Hirsch | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 14 Feb 2025 | 9,370 | 423,145 | - | 3.2 | 29,797 | Common Stock |
| Andrew J. Hirsch | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 223,500 | 445,362 | - | 0 | Common Stock | |
| Mark Mossler | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 14 Feb 2025 | 1,586 | 18,204 | - | 3.2 | 5,043 | Common Stock |
| Paige Mahaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 42,400 | 42,400 | - | - | Stock Option (Right to Buy) | |
| Paige Mahaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 28,200 | 105,000 | - | 0 | Common Stock | |
| Jolie M. Siegel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 13 Feb 2025 | 2,135 | 54,353 | - | 3.2 | 6,832 | Common Stock |
| Jolie M. Siegel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 84,700 | 84,700 | - | - | Stock Option (Right to Buy) | |
| Jolie M. Siegel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 13 Feb 2025 | 2,914 | 107,939 | - | 3.2 | 9,267 | Common Stock |
| Jolie M. Siegel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 56,500 | 110,853 | - | 0 | Common Stock | |
| Kelly A. Schick | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 13 Feb 2025 | 1,735 | 54,753 | - | 3.2 | 5,552 | Common Stock |
| Kelly A. Schick | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 56,500 | 111,253 | - | 0 | Common Stock | |
| Kelly A. Schick | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 13 Feb 2025 | 2,368 | 108,885 | - | 3.2 | 7,530 | Common Stock |
| Kelly A. Schick | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 84,700 | 84,700 | - | - | Stock Option (Right to Buy) | |
| Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 13 Feb 2025 | 2,368 | 108,474 | - | 3.2 | 7,530 | Common Stock |
| Scott N. Boyle | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 84,700 | 84,700 | - | - | Stock Option (Right to Buy) | |
| Scott N. Boyle | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 3.15 per share. | 13 Feb 2025 | 490 | 110,842 | - | 3.2 | 1,544 | Common Stock |
| Scott N. Boyle | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 56,500 | 111,332 | - | 0 | Common Stock | |
| Scott N. Boyle | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 3.15 per share. | 13 Feb 2025 | 669 | 107,805 | - | 3.1 | 2,107 | Common Stock |
| Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 13 Feb 2025 | 1,735 | 54,832 | - | 3.2 | 5,552 | Common Stock |
| Kendra Adams | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 87,100 | 169,676 | - | 0 | Common Stock | |
| Kendra Adams | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 13 Feb 2025 | 1,863 | 82,576 | - | 3.2 | 5,962 | Common Stock |
| Kendra Adams | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 13 Feb 2025 | 4,559 | 165,117 | - | 3.2 | 14,498 | Common Stock |
| Kendra Adams | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 130,600 | 130,600 | - | - | Stock Option (Right to Buy) | |
| Donna Roy Grogan | Director | Grant, award, or other acquisition of securities at price $ 3.66 per share. | 02 Jan 2025 | 3,757 | 32,699 | - | 3.7 | 13,751 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 3.66 per share. | 02 Jan 2025 | 3,074 | 119,768 | - | 3.7 | 11,251 | Common Stock |
| Steven L. Hoerter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2024 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Andrew J. Hirsch | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 12,500 | 227,412 | - | - | Common Stock | |
| Andrew J. Hirsch | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 12,500 | 35,000 | - | - | Performance Restricted Stock Units | |
| Andrew J. Hirsch | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.04 per share. | 07 Nov 2024 | 5,550 | 221,862 | - | 6.0 | 33,522 | Common Stock |
| Jolie M. Siegel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 10,500 | - | - | Performance Restricted Stock Units | |
| Jolie M. Siegel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 57,590 | - | - | Common Stock | |
| Jolie M. Siegel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.04 per share. | 07 Nov 2024 | 1,102 | 56,488 | - | 6.0 | 6,656 | Common Stock |
| Kelly A. Schick | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 57,590 | - | - | Common Stock | |
| Kelly A. Schick | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 10,500 | - | - | Performance Restricted Stock Units | |
| Kelly A. Schick | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.04 per share. | 07 Nov 2024 | 1,102 | 56,488 | - | 6.0 | 6,656 | Common Stock |
| Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 57,669 | - | - | Common Stock | |
| Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 10,500 | - | - | Performance Restricted Stock Units | |
| Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.04 per share. | 07 Nov 2024 | 1,102 | 56,567 | - | 6.0 | 6,656 | Common Stock |
| Kendra Adams | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 85,541 | - | - | Common Stock | |
| Kendra Adams | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.04 per share. | 07 Nov 2024 | 1,102 | 84,439 | - | 6.0 | 6,656 | Common Stock |
| Kendra Adams | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 10,500 | - | - | Performance Restricted Stock Units | |
| Paige Mahaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2024 | 345,600 | 345,600 | - | - | Stock Option (Right to Buy) | |
| Paige Mahaney | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2024 | 76,800 | 76,800 | - | 0 | Common Stock | |
| Donna Roy Grogan | Director | Grant, award, or other acquisition of securities at price $ 5.56 per share. | 01 Oct 2024 | 2,474 | 28,942 | - | 5.6 | 13,755 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 5.56 per share. | 01 Oct 2024 | 2,023 | 116,694 | - | 5.6 | 11,248 | Common Stock |
| Kendra Adams | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.38 per share. | 18 Sep 2024 | 1,837 | 81,791 | - | 6.4 | 11,720 | Common Stock |
| Andrew J. Hirsch | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 7,500 | 218,241 | - | - | Common Stock | |
| Andrew J. Hirsch | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 7,500 | 47,500 | - | - | Performance Restricted Stock Units | |
| Andrew J. Hirsch | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.36 per share. | 16 Sep 2024 | 3,329 | 214,912 | - | 6.4 | 21,172 | Common Stock |
| Jolie M. Siegel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 14,250 | - | - | Performance Restricted Stock Units | |
| Jolie M. Siegel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 54,501 | - | - | Common Stock | |
| Jolie M. Siegel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.36 per share. | 16 Sep 2024 | 661 | 53,840 | - | 6.4 | 4,204 | Common Stock |
| Kelly A. Schick | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.36 per share. | 16 Sep 2024 | 661 | 53,840 | - | 6.4 | 4,204 | Common Stock |
| Kelly A. Schick | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 14,250 | - | - | Performance Restricted Stock Units | |
| Kelly A. Schick | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 54,501 | - | - | Common Stock | |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 14,250 | - | - | Performance Restricted Stock Units | |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 131,371 | - | - | Common Stock | |
| Stewart Fisher | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.36 per share. | 16 Sep 2024 | 661 | 130,710 | - | 6.4 | 4,204 | Common Stock |
| Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.36 per share. | 16 Sep 2024 | 661 | 53,919 | - | 6.4 | 4,204 | Common Stock |
| Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 14,250 | - | - | Performance Restricted Stock Units | |
| Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 54,580 | - | - | Common Stock | |
| Kendra Adams | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 14,250 | - | - | Performance Restricted Stock Units | |
| Kendra Adams | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.36 per share. | 16 Sep 2024 | 661 | 83,628 | - | 6.4 | 4,204 | Common Stock |
| Kendra Adams | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 84,289 | - | - | Common Stock | |
| Stephen Fawell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2024 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Leonard M.J. Reyno | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.00 per share. | 10 Jul 2024 | 6,191 | 91,809 | - | 5 | 30,955 | Common Stock |
| Donna Roy Grogan | Director | Grant, award, or other acquisition of securities at price $ 4.85 per share. | 01 Jul 2024 | 2,836 | 26,468 | - | 4.9 | 13,755 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 4.85 per share. | 01 Jul 2024 | 2,320 | 114,671 | - | 4.9 | 11,252 | Common Stock |
| Bruce L. Downey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 32,500 | 32,500 | - | - | Stock Option (Right to Buy) | |
| Owen P. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 32,500 | 32,500 | - | - | Stock Option (Right to Buy) | |
| Donna Roy Grogan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 32,500 | 32,500 | - | - | Stock Option (Right to Buy) | |
| Utpal Koppikar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 32,500 | 32,500 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 32,500 | 32,500 | - | - | Stock Option (Right to Buy) | |
| Laura Bessen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 32,500 | 32,500 | - | - | Stock Option (Right to Buy) | |
| Malcolm Salter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 32,500 | 32,500 | - | - | Stock Option (Right to Buy) | |
| Ronald H.W. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Donna Roy Grogan | Director | Grant, award, or other acquisition of securities at price $ 8.10 per share. | 01 Apr 2024 | 1,697 | 23,632 | - | 8.1 | 13,746 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 8.10 per share. | 01 Apr 2024 | 1,389 | 112,351 | - | 8.1 | 11,251 | Common Stock |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 8.10 per share. | 01 Apr 2024 | 1,358 | 22,075 | - | 8.1 | 11,000 | Common Stock |
| Jolie Siegel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Jolie Siegel | Chief Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Mar 2024 | 84,850 | 0 | - | - | Stock Option (Right to Buy) | |
| Jolie Siegel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 84,850 | 84,850 | - | - | Stock Option (Right to Buy) | |
| Jolie Siegel | Chief Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Mar 2024 | 90,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kelly Schick | Chief People Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Mar 2024 | 78,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Kelly Schick | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 78,500 | 78,500 | - | - | Stock Option (Right to Buy) | |
| Kelly Schick | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 92,000 | 92,000 | - | - | Stock Option (Right to Buy) | |
| Kelly Schick | Chief People Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Mar 2024 | 92,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Stewart Fisher | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 118,000 | 118,000 | - | - | Stock Option (Right to Buy) | |
| Stewart Fisher | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Mar 2024 | 118,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Stewart Fisher | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 94,950 | 94,950 | - | - | Stock Option (Right to Buy) | |
| Stewart Fisher | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Mar 2024 | 94,950 | 0 | - | - | Stock Option (Right to Buy) | |
| Scott N. Boyle | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| Scott N. Boyle | Chief Business Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Mar 2024 | 115,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kendra Adams | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Mar 2024 | 45,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kendra Adams | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Hirsch Andrew J. | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.90 per share. | 15 Feb 2024 | 6,560 | 210,741 | - | 7.9 | 51,824 | Common Stock |
| M.J. Leonard Reyno | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 165,300 | 165,300 | - | - | Stock Option (Right to Buy) | |
| J. Andrew Hirsch | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 465,500 | 465,500 | - | - | Stock Option (Right to Buy) | |
| Reyno Leonard M.J. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 36,700 | 98,000 | - | 0 | Common Stock | |
| Andrew J. Hirsch | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 103,400 | 217,301 | - | 0 | Common Stock | |
| Mark Mossler | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 27,430 | 27,430 | - | - | Stock Option (Right to Buy) | |
| Mark Mossler | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 18,290 | 19,790 | - | 0 | Common Stock | |
| Fisher Stewart | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.53 per share. | 13 Feb 2024 | 2,255 | 101,821 | - | 6.5 | 14,725 | Common Stock |
| Adams Kendra | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.53 per share. | 13 Feb 2024 | 1,301 | 45,339 | - | 6.5 | 8,496 | Common Stock |
| Jolie Siegel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 27,300 | 52,251 | - | 0 | Common Stock | |
| Fisher Stewart | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 122,800 | 122,800 | - | - | Stock Option (Right to Buy) | |
| Kendra Adams | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 36,700 | 82,039 | - | 0 | Common Stock | |
| Schick Kelly | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 122,800 | 122,800 | - | - | Stock Option (Right to Buy) | |
| Fisher Stewart | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 27,300 | 129,121 | - | 0 | Common Stock | |
| Siegel Jolie | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 122,800 | 122,800 | - | - | Stock Option (Right to Buy) | |
| Scott Boyle N. | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 27,300 | 52,330 | - | 0 | Common Stock | |
| Siegel Jolie | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.53 per share. | 13 Feb 2024 | 1,735 | 24,951 | - | 6.5 | 11,330 | Common Stock |
| Boyle N. Scott | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.53 per share. | 13 Feb 2024 | 1,735 | 25,030 | - | 6.5 | 11,330 | Common Stock |
| Adams Kendra | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 165,300 | 165,300 | - | - | Stock Option (Right to Buy) | |
| Boyle Scott N. | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 122,800 | 122,800 | - | - | Stock Option (Right to Buy) | |
| Schick Kelly | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 27,300 | 52,251 | - | 0 | Common Stock | |
| Schick Kelly | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.53 per share. | 13 Feb 2024 | 1,735 | 24,951 | - | 6.5 | 11,330 | Common Stock |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 6.52 per share. | 02 Jan 2024 | 1,687 | 20,717 | - | 6.5 | 10,999 | Common Stock |
| Anderson Kenneth C. | Director | Grant, award, or other acquisition of securities at price $ 6.52 per share. | 02 Jan 2024 | 1,725 | 110,962 | - | 6.5 | 11,247 | Common Stock |
| Donna Roy Grogan | Director | Grant, award, or other acquisition of securities at price $ 6.52 per share. | 02 Jan 2024 | 2,108 | 21,935 | - | 6.5 | 13,744 | Common Stock |
| Andrew J. Hirsch | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 7,500 | 55,000 | - | - | Performance Restricted Stock Units | |
| Andrew J. Hirsch | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 7,500 | 116,106 | - | - | Common Stock | |
| Andrew J. Hirsch | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.93 per share. | 30 Aug 2023 | 2,205 | 113,901 | - | 2.9 | 6,461 | Common Stock |
| Jolie Siegel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 27,347 | - | - | Common Stock | |
| Jolie Siegel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 16,500 | - | - | Performance Restricted Stock Units | |
| Jolie Siegel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.93 per share. | 30 Aug 2023 | 661 | 26,686 | - | 2.9 | 1,937 | Common Stock |
| Kelly Schick | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 27,347 | - | - | Common Stock | |
| Kelly Schick | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 16,500 | - | - | Performance Restricted Stock Units | |
| Kelly Schick | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.93 per share. | 30 Aug 2023 | 661 | 26,686 | - | 2.9 | 1,937 | Common Stock |
| Stewart Fisher | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.93 per share. | 30 Aug 2023 | 661 | 104,076 | - | 2.9 | 1,937 | Common Stock |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 16,500 | - | - | Performance Restricted Stock Units | |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 104,737 | - | - | Common Stock | |
| Lauren White | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 16,500 | - | - | Performance Restricted Stock Units | |
| Lauren White | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 33,347 | - | - | Common Stock | |
| Lauren White | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.93 per share. | 30 Aug 2023 | 661 | 32,686 | - | 2.9 | 1,937 | Common Stock |
| Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 16,500 | - | - | Performance Restricted Stock Units | |
| Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.93 per share. | 30 Aug 2023 | 661 | 26,765 | - | 2.9 | 1,937 | Common Stock |
| Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 27,426 | - | - | Common Stock | |
| Leonard M.J. Reyno | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 61,300 | 61,300 | - | 0 | Common Stock | |
| Leonard M.J. Reyno | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 276,000 | 276,000 | - | - | Stock Option (Right to Buy) | |
| Donna Roy Grogan | Director | Grant, award, or other acquisition of securities at price $ 2.83 per share. | 03 Jul 2023 | 4,858 | 11,738 | - | 2.8 | 13,748 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 2.83 per share. | 03 Jul 2023 | 3,976 | 102,620 | - | 2.8 | 11,252 | Common Stock |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 2.83 per share. | 03 Jul 2023 | 3,887 | 12,560 | - | 2.8 | 11,000 | Common Stock |
| Bruce L. Downey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Donna Roy Grogan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Utpal Koppikar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Malcolm Salter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Laura Bessen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Donna Roy Grogan | Director | Grant, award, or other acquisition of securities at price $ 3.20 per share. | 03 Apr 2023 | 4,298 | 6,880 | - | 3.2 | 13,754 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 3.20 per share. | 03 Apr 2023 | 3,516 | 98,644 | - | 3.2 | 11,251 | Common Stock |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 3.20 per share. | 03 Apr 2023 | 3,438 | 8,673 | - | 3.2 | 11,002 | Common Stock |
| Andrew J. Hirsch | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 367,200 | 367,200 | - | - | Stock Option (Right to Buy) | |
| Andrew J. Hirsch | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 81,600 | 108,606 | - | 0 | Common Stock | |
| Jolie Siegel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Jolie Siegel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 20,000 | 25,097 | - | 0 | Common Stock | |
| Kelly Schick | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Kelly Schick | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 20,000 | 25,097 | - | 0 | Common Stock | |
| Stewart Fisher | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Stewart Fisher | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 26,000 | 102,487 | - | 0 | Common Stock | |
| Lauren White | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Lauren White | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 26,000 | 31,097 | - | 0 | Common Stock | |
| Scott N. Boyle | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Scott N. Boyle | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 20,000 | 25,176 | - | 0 | Common Stock | |
| Utpal Koppikar | Director | Purchase of securities on an exchange or from another person at price $ 5.60 per share. | 08 Feb 2023 | 5,667 | 5,667 | - | 5.6 | 31,735 | Common Stock |
| Andrew J. Hirsch | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 12,500 | 31,325 | - | - | Common Stock | |
| Andrew J. Hirsch | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 12,500 | 62,500 | - | - | Performance Restricted Stock Units | |
| Andrew J. Hirsch | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 30 Jan 2023 | 4,319 | 27,006 | - | 7.8 | 33,602 | Common Stock |
| Jolie Siegel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 6,398 | - | - | Common Stock | |
| Jolie Siegel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 18,750 | - | - | Performance Restricted Stock Units | |
| Jolie Siegel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 30 Jan 2023 | 1,301 | 5,097 | - | 7.8 | 10,122 | Common Stock |
| Kelly Schick | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 6,398 | - | - | Common Stock | |
| Kelly Schick | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 18,750 | - | - | Performance Restricted Stock Units | |
| Kelly Schick | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 30 Jan 2023 | 1,301 | 5,097 | - | 7.8 | 10,122 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 21,398 | - | - | Common Stock | |
| Adam Crystal | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 30 Jan 2023 | 1,301 | 20,097 | - | 7.8 | 10,122 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 18,750 | - | - | Performance Restricted Stock Units | |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 77,788 | - | - | Common Stock | |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 18,750 | - | - | Performance Restricted Stock Units | |
| Stewart Fisher | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 30 Jan 2023 | 1,301 | 76,487 | - | 7.8 | 10,122 | Common Stock |
| Lauren White | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 6,398 | - | - | Common Stock | |
| Lauren White | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 18,750 | - | - | Performance Restricted Stock Units | |
| Lauren White | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 30 Jan 2023 | 1,301 | 5,097 | - | 7.8 | 10,122 | Common Stock |
| Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 18,750 | - | - | Performance Restricted Stock Units | |
| Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 6,398 | - | - | Common Stock | |
| Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 30 Jan 2023 | 1,222 | 5,176 | - | 7.8 | 9,507 | Common Stock |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 06 Jan 2023 | 268 | 94,684 | - | 2.1 | 565 | Common Stock |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2023 | 444 | 890 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2023 | 268 | 1,067 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 06 Jan 2023 | 444 | 95,128 | - | 5.0 | 2,211 | Common Stock |
| Donna Roy Grogan | Director | Grant, award, or other acquisition of securities at price $ 6.38 per share. | 03 Jan 2023 | 1,763 | 2,582 | - | 6.4 | 11,248 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 6.38 per share. | 03 Jan 2023 | 1,568 | 94,416 | - | 6.4 | 10,004 | Common Stock |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 6.38 per share. | 03 Jan 2023 | 1,725 | 5,235 | - | 6.4 | 11,006 | Common Stock |
| Donna Roy Grogan | Director | Grant, award, or other acquisition of securities at price $ 8.69 per share. | 03 Oct 2022 | 819 | 819 | - | 8.7 | 7,117 | Common Stock |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 267 | 1,335 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 445 | 1,334 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 03 Oct 2022 | 267 | 91,253 | - | 2.1 | 563 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 8.69 per share. | 03 Oct 2022 | 1,150 | 92,848 | - | 8.7 | 9,994 | Common Stock |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 03 Oct 2022 | 445 | 91,698 | - | 5.0 | 2,216 | Common Stock |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 8.69 per share. | 03 Oct 2022 | 1,265 | 3,510 | - | 8.7 | 10,993 | Common Stock |
| Donna Roy Grogan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2022 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Laura Bessen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2022 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 15 Jul 2022 | 889 | 90,986 | - | 5.0 | 4,427 | Common Stock |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 889 | 1,779 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 535 | 1,602 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 15 Jul 2022 | 535 | 90,097 | - | 2.1 | 1,129 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 8.03 per share. | 01 Jul 2022 | 1,246 | 89,562 | - | 8.0 | 10,005 | Common Stock |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 8.03 per share. | 01 Jul 2022 | 1,372 | 2,245 | - | 8.0 | 11,017 | Common Stock |
| Bruce L. Downey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Marc A. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Malcolm Salter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Andrew J. Hirsch | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.01 per share. | 26 May 2022 | 3,675 | 18,825 | - | 7.0 | 25,762 | Common Stock |
| Jolie Siegel | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.01 per share. | 26 May 2022 | 1,102 | 2,648 | - | 7.0 | 7,725 | Common Stock |
| Kelly Schick | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.01 per share. | 26 May 2022 | 1,102 | 2,648 | - | 7.0 | 7,725 | Common Stock |
| Adam Crystal | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.01 per share. | 26 May 2022 | 1,102 | 17,648 | - | 7.0 | 7,725 | Common Stock |
| Stewart Fisher | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.01 per share. | 26 May 2022 | 1,102 | 74,038 | - | 7.0 | 7,725 | Common Stock |
| Lauren White | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.01 per share. | 26 May 2022 | 1,102 | 2,648 | - | 7.0 | 7,725 | Common Stock |
| Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.01 per share. | 26 May 2022 | 1,102 | 2,648 | - | 7.0 | 7,725 | Common Stock |
| Andrew J. Hirsch | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 8.40 per share. | 12 Apr 2022 | 10,000 | 10,000 | - | 8.4 | 84,000 | Common Stock |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.71 per share. | 12 Apr 2022 | 2,156 | 45,462 | - | 3.7 | 7,999 | Common Stock |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2022 | 2,156 | 35,572 | - | - | Stock Option (Right to Buy) | |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 12 Apr 2022 | 25,928 | 71,390 | - | 5.0 | 129,121 | Common Stock |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2022 | 25,928 | 48,152 | - | - | Stock Option (Right to Buy) | |
| Alain J. Cohen | Director | Grant, award, or other acquisition of securities at price $ 26.46 per share. | 04 Apr 2022 | 388 | 928 | - | 26.5 | 10,266 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 26.46 per share. | 04 Apr 2022 | 341 | 88,316 | - | 26.5 | 9,023 | Common Stock |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 26.46 per share. | 04 Apr 2022 | 379 | 873 | - | 26.5 | 10,028 | Common Stock |
| Utpal Koppikar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2022 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Andrew J. Hirsch | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 87,500 | 87,500 | - | - | Performance Restricted Stock Units | |
| Jolie Siegel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 26,250 | 26,250 | - | - | Performance Restricted Stock Units | |
| Jolie Siegel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Adam Crystal | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 26,250 | 26,250 | - | - | Performance Restricted Stock Units | |
| Adam Crystal | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 118,000 | 118,000 | - | - | Stock Option (Right to Buy) | |
| Stewart Fisher | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 118,000 | 118,000 | - | - | Stock Option (Right to Buy) | |
| Stewart Fisher | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 26,250 | 26,250 | - | - | Performance Restricted Stock Units | |
| Lauren White | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 26,250 | 26,250 | - | - | Performance Restricted Stock Units | |
| Lauren White | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 26 Jan 2022 | 803 | 86,641 | - | 2.1 | 1,694 | Common Stock |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2022 | 1,334 | 2,668 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2022 | 803 | 2,137 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 26 Jan 2022 | 1,334 | 87,975 | - | 5.0 | 6,643 | Common Stock |
| Alain J. Cohen | Director | Grant, award, or other acquisition of securities at price $ 31.58 per share. | 04 Jan 2022 | 318 | 540 | - | 31.6 | 10,042 | Common Stock |
| Marc A. Cohen | Director | Grant, award, or other acquisition of securities at price $ 31.58 per share. | 04 Jan 2022 | 657 | 1,118 | - | 31.6 | 20,748 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 04 Jan 2022 | 15,000 | 30,000 | - | 6.5 | 97,350 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 15,000 | 112,292 | - | - | Stock Option (Right to Buy) | |
| Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.66 per share. | 04 Jan 2022 | 1,054 | 15,000 | - | 32.7 | 34,420 | Common Stock |
| Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.59 per share. | 04 Jan 2022 | 13,946 | 16,054 | - | 31.6 | 440,547 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 31.58 per share. | 04 Jan 2022 | 278 | 85,838 | - | 31.6 | 8,779 | Common Stock |
| Malcolm Salter | Director | Grant, award, or other acquisition of securities at price $ 31.58 per share. | 04 Jan 2022 | 428 | 11,380 | - | 31.6 | 13,516 | Common Stock |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 31.58 per share. | 04 Jan 2022 | 199 | 494 | - | 31.6 | 6,284 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2021 | 5,000 | 127,292 | - | - | Stock Option (Right to Buy) | |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 22 Dec 2021 | 5,000 | 15,000 | - | 6.5 | 32,450 | Common Stock |
| Malcolm Salter | Director | Sale of securities on an exchange or to another person at price $ 30.25 per share. | 17 Dec 2021 | 755 | 10,952 | - | 30.3 | 22,839 | Common Stock |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2021 | 2,373 | 0 | - | - | Stock Option (Right to Buy) | |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 08 Dec 2021 | 403 | 43,306 | - | 5.0 | 2,007 | Common Stock |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 08 Dec 2021 | 2,373 | 25,117 | - | 2.1 | 5,007 | Common Stock |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.71 per share. | 08 Dec 2021 | 17,786 | 42,903 | - | 3.7 | 65,986 | Common Stock |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2021 | 403 | 203,994 | - | - | Stock Option (Right to Buy) | |
| Stewart Fisher | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2021 | 17,786 | 37,728 | - | - | Stock Option (Right to Buy) | |
| Malcolm Salter | Director | Sale of securities on an exchange or to another person at price $ 40.11 per share. | 19 Nov 2021 | 755 | 11,707 | - | 40.1 | 30,283 | Common Stock |
| Malcolm Salter | Director | Sale of securities on an exchange or to another person at price $ 44.94 per share. | 15 Oct 2021 | 755 | 12,462 | - | 44.9 | 33,930 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2021 | 10,000 | 132,292 | - | - | Stock Option (Right to Buy) | |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 08 Oct 2021 | 10,000 | 10,000 | - | 6.5 | 64,900 | Common Stock |
| Alain J. Cohen | Director | Grant, award, or other acquisition of securities at price $ 44.99 per share. | 04 Oct 2021 | 222 | 222 | - | 45.0 | 9,988 | Common Stock |
| Marc A. Cohen | Director | Grant, award, or other acquisition of securities at price $ 44.99 per share. | 04 Oct 2021 | 461 | 461 | - | 45.0 | 20,740 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 44.99 per share. | 04 Oct 2021 | 194 | 85,560 | - | 45.0 | 8,728 | Common Stock |
| Malcolm Salter | Director | Grant, award, or other acquisition of securities at price $ 44.99 per share. | 04 Oct 2021 | 300 | 13,217 | - | 45.0 | 13,497 | Common Stock |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 44.99 per share. | 04 Oct 2021 | 138 | 295 | - | 45.0 | 6,209 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 01 Oct 2021 | 15,000 | 15,000 | - | 5.0 | 74,700 | Common Stock |
| Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.99 per share. | 01 Oct 2021 | 5,112 | 0 | - | 46.0 | 235,119 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 15,000 | 168,108 | - | - | Stock Option (Right to Buy) | |
| Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.32 per share. | 01 Oct 2021 | 8,176 | 5,112 | - | 45.3 | 370,563 | Common Stock |
| Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 44.25 per share. | 01 Oct 2021 | 1,712 | 13,288 | - | 44.3 | 75,756 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.04 per share. | 27 Sep 2021 | 539 | 31,681 | - | 50.0 | 26,969 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.04 per share. | 27 Sep 2021 | 1,311 | 503,126 | - | 50.0 | 65,604 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.10 per share. | 22 Sep 2021 | 3,544 | 39,492 | - | 50.1 | 177,554 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.10 per share. | 22 Sep 2021 | 2,115 | 504,437 | - | 50.1 | 105,964 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.11 per share. | 22 Sep 2021 | 900 | 32,220 | - | 50.1 | 45,101 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 51.08 per share. | 22 Sep 2021 | 1,007 | 506,552 | - | 51.1 | 51,435 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.35 per share. | 22 Sep 2021 | 11,801 | 507,559 | - | 50.4 | 594,193 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 51.09 per share. | 22 Sep 2021 | 446 | 33,120 | - | 51.1 | 22,784 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.35 per share. | 22 Sep 2021 | 5,926 | 33,566 | - | 50.3 | 298,359 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.09 per share. | 22 Sep 2021 | 7,004 | 519,360 | - | 50.1 | 350,860 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.04 per share. | 17 Sep 2021 | 5,152 | 48,024 | - | 50.0 | 257,808 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.14 per share. | 17 Sep 2021 | 5,333 | 526,364 | - | 50.1 | 267,410 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.13 per share. | 17 Sep 2021 | 4,988 | 43,036 | - | 50.1 | 250,051 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.05 per share. | 17 Sep 2021 | 5,688 | 531,697 | - | 50.1 | 284,687 | Common Stock |
| Malcolm Salter | Director | Sale of securities on an exchange or to another person at price $ 49.89 per share. | 17 Sep 2021 | 755 | 12,917 | - | 49.9 | 37,667 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.03 per share. | 14 Sep 2021 | 492 | 587,731 | - | 50.0 | 24,614 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.01 per share. | 14 Sep 2021 | 346 | 510,385 | - | 50.0 | 17,305 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 48.62 per share. | 14 Sep 2021 | 25,807 | 510,731 | - | 48.6 | 1,254,677 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.01 per share. | 14 Sep 2021 | 346 | 53,176 | - | 50.0 | 17,303 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 48.97 per share. | 14 Sep 2021 | 24,193 | 563,538 | - | 49.0 | 1,184,690 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 48.71 per share. | 14 Sep 2021 | 30,000 | 53,522 | - | 48.7 | 1,461,204 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.01 per share. | 14 Sep 2021 | 492 | 83,522 | - | 50.0 | 24,603 | Common Stock |
| Jolie Siegel | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 10 Sep 2021 | 12,500 | 0 | - | 50 | 625,000 | Common Stock |
| Jolie Siegel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 12,500 | 271,321 | - | - | Stock Option (Right to Buy) | |
| Jolie Siegel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 10 Sep 2021 | 12,500 | 12,500 | - | 5.0 | 62,250 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.01 per share. | 10 Sep 2021 | 1,320 | 591,553 | - | 50.0 | 66,010 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 10 Sep 2021 | 1,230 | 87,344 | - | 50.0 | 61,501 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.07 per share. | 10 Sep 2021 | 3,330 | 588,223 | - | 50.1 | 166,743 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 50.07 per share. | 10 Sep 2021 | 3,330 | 84,014 | - | 50.1 | 166,730 | Common Stock |
| Malcolm Salter | Director | Sale of securities on an exchange or to another person at price $ 40.73 per share. | 20 Aug 2021 | 755 | 13,672 | - | 40.7 | 30,751 | Common Stock |
| Stewart Fisher | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 45.01 per share. | 03 Aug 2021 | 17,057 | 22,744 | - | 45.0 | 767,812 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 45.16 per share. | 03 Aug 2021 | 14,407 | 88,574 | - | 45.2 | 650,587 | Common Stock |
| Jolie Siegel | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 29 Jul 2021 | 12,500 | 0 | - | 45 | 562,500 | Common Stock |
| Jolie Siegel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2021 | 12,500 | 283,821 | - | - | Stock Option (Right to Buy) | |
| Jolie Siegel | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 29 Jul 2021 | 12,500 | 12,500 | - | 5.0 | 62,250 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 29 Jul 2021 | 15,000 | 15,000 | - | 5.0 | 74,700 | Common Stock |
| Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 29 Jul 2021 | 15,000 | 0 | - | 45 | 675,000 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2021 | 15,000 | 183,108 | - | - | Stock Option (Right to Buy) | |
| Stewart Fisher | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 29 Jul 2021 | 18,104 | 39,801 | - | 45.0 | 814,756 | Common Stock |
| Stewart Fisher | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 29 Jul 2021 | 50,211 | 57,905 | - | 45.0 | 2,259,631 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 29 Jul 2021 | 11,336 | 107,238 | - | 45.0 | 510,168 | Common Stock |
| Elena Prokupets | Director | Sale of securities on an exchange or to another person at price $ 45.01 per share. | 29 Jul 2021 | 4,257 | 102,981 | - | 45.0 | 191,606 | Common Stock |
| Malcolm Salter | Director | Sale of securities on an exchange or to another person at price $ 37.37 per share. | 16 Jul 2021 | 755 | 14,427 | - | 37.4 | 28,214 | Common Stock |
| Alain J. Cohen | Director | Grant, award, or other acquisition of securities at price $ 39.72 per share. | 02 Jul 2021 | 251 | 517 | - | 39.7 | 9,970 | Common Stock |
| Marc A. Cohen | Director | Grant, award, or other acquisition of securities at price $ 39.72 per share. | 02 Jul 2021 | 522 | 6,641 | - | 39.7 | 20,734 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 39.72 per share. | 02 Jul 2021 | 220 | 85,366 | - | 39.7 | 8,738 | Common Stock |
| Malcolm Salter | Director | Grant, award, or other acquisition of securities at price $ 39.72 per share. | 02 Jul 2021 | 339 | 15,182 | - | 39.7 | 13,465 | Common Stock |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 39.72 per share. | 02 Jul 2021 | 157 | 157 | - | 39.7 | 6,236 | Common Stock |
| Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.93 per share. | 01 Jul 2021 | 13,300 | 1,700 | - | 37.9 | 504,420 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.50 per share. | 01 Jul 2021 | 15,000 | 15,000 | - | 6.5 | 97,500 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 15,000 | 142,292 | - | - | Stock Option (Right to Buy) | |
| Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.38 per share. | 01 Jul 2021 | 1,700 | 0 | - | 38.4 | 65,246 | Common Stock |
| Lauren White | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 136,000 | 136,000 | - | - | Stock Option (Right to Buy) | |
| Malcolm Salter | Director | Sale of securities on an exchange or to another person at price $ 37.19 per share. | 18 Jun 2021 | 755 | 14,843 | - | 37.2 | 28,078 | Common Stock |
| Bruce L. Downey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Alain J. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Marc A. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Elena Prokupets | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Malcolm Salter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Alain J. Cohen | Director | Other type of transaction at price $ 0.00 per share. | 14 Jun 2021 | 61,877 | 62,143 | - | 0 | Common Stock | |
| Alain J. Cohen | Director | Other type of transaction at price $ 0.00 per share. | 14 Jun 2021 | 22,598 | 1,741,930 | - | 0 | Common Stock | |
| Marc A. Cohen | Director | Other type of transaction at price $ 0.00 per share. | 14 Jun 2021 | 92,817 | 98,936 | - | 0 | Common Stock | |
| Marc A. Cohen | Director | Other type of transaction at price $ 0.00 per share. | 14 Jun 2021 | 22,598 | 1,874,805 | - | 0 | Common Stock | |
| Malcolm Salter | Director | Sale of securities on an exchange or to another person at price $ 37.12 per share. | 21 May 2021 | 755 | 15,598 | - | 37.1 | 28,026 | Common Stock |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2021 | 444 | 4,002 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2021 | 267 | 2,940 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 14 Apr 2021 | 444 | 85,146 | - | 5.0 | 2,211 | Common Stock |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 14 Apr 2021 | 267 | 84,702 | - | 2.1 | 563 | Common Stock |
| Kenneth C. Anderson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Apr 2021 | 2,278 | 47,316 | - | 0 | Common Stock | |
| Kenneth C. Anderson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Apr 2021 | 2,278 | 84,435 | - | 0 | Common Stock | |
| Alain J. Cohen | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 37.51 per share. | 05 Apr 2021 | 266 | 266 | - | 37.5 | 9,978 | Common Stock |
| Marc A. Cohen | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 37.51 per share. | 05 Apr 2021 | 553 | 6,119 | - | 37.5 | 20,743 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.50 per share. | 05 Apr 2021 | 15,000 | 15,000 | - | 6.5 | 97,500 | Common Stock |
| Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2021 | 15,000 | 157,292 | - | - | Common Stock | |
| Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.00 per share. | 05 Apr 2021 | 10,879 | 0 | - | 38.0 | 413,407 | Common Stock |
| Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.16 per share. | 05 Apr 2021 | 4,121 | 10,879 | - | 37.2 | 153,129 | Common Stock |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 37.51 per share. | 05 Apr 2021 | 233 | 82,157 | - | 37.5 | 8,740 | Common Stock |
| Malcolm Salter | Director | Grant, award, or other acquisition of securities at price $ 37.51 per share. | 05 Apr 2021 | 359 | 16,353 | - | 37.5 | 13,466 | Common Stock |
| Glenn Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 41,200 | 41,200 | - | - | Stock Option (Right to Buy) | |
| Marc A. Cohen | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 536 | 3,209 | - | - | Stock Option (Right to Buy) | |
| Marc A. Cohen | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 18 Feb 2021 | 536 | 5,566 | - | 2.1 | 1,131 | Common Stock |
| Jolie Siegel | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 84,850 | 84,850 | - | - | Stock Option (Right to Buy) | |
| Adam Crystal | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 87,850 | 87,850 | - | - | Stock Option (Right to Buy) | |
| Stewart Fisher | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 94,950 | 94,950 | - | - | Stock Option (Right to Buy) | |
| Laura Jean Wahlberg | VP of Finance Corp Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 23,100 | 23,100 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 22 Jan 2021 | 889 | 81,924 | - | 5.0 | 4,427 | Common Stock |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 889 | 4,446 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 121 | 0 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 538 | 3,207 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 22 Jan 2021 | 121 | 81,035 | - | 2.1 | 255 | Common Stock |
| Kenneth C. Anderson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 22 Jan 2021 | 538 | 80,914 | - | 2.1 | 1,135 | Common Stock |
| Bruce L. Downey | Director | 06 Oct 2020 | 2,128,571 | 0 | - | - | Series B Preferred Stock | ||
| Bruce L. Downey | Director | 06 Oct 2020 | 2,000,000 | 0 | - | - | Series A Preferred Stock | ||
| Bruce L. Downey | Director | 06 Oct 2020 | 252,394 | 489,542 | - | - | Common Stock | ||
| Bruce L. Downey | Director | 06 Oct 2020 | 237,148 | 237,148 | - | - | Common Stock | ||
| Alain J. Cohen | Director, Ten Percent Owner | 06 Oct 2020 | 2,000,000 | 0 | - | - | Series Seed Preferred Stock | ||
| Alain J. Cohen | Director, Ten Percent Owner | 06 Oct 2020 | 20,952,403 | 0 | - | - | Series B Preferred Stock | ||
| Alain J. Cohen | Director, Ten Percent Owner | 06 Oct 2020 | 12,500,000 | 0 | - | - | Series A Preferred Stock | ||
| Alain J. Cohen | Director, Ten Percent Owner | 06 Oct 2020 | 237,149 | 237,149 | - | - | Common Stock | ||
| Alain J. Cohen | Director, Ten Percent Owner | 06 Oct 2020 | 1,482,183 | 1,719,332 | - | - | Common Stock | ||
| Alain J. Cohen | Director, Ten Percent Owner | 06 Oct 2020 | 2,484,425 | 2,484,425 | - | - | Common Stock | ||
| Marc A. Cohen | Director, Ten Percent Owner | 06 Oct 2020 | 12,500,000 | 0 | - | - | Series A Preferred Stock | ||
| Marc A. Cohen | Director, Ten Percent Owner | 06 Oct 2020 | 20,952,403 | 0 | - | - | Series B Preferred Stock | ||
| Marc A. Cohen | Director, Ten Percent Owner | 06 Oct 2020 | 2,000,000 | 0 | - | - | Series Seed Preferred Stock | ||
| Marc A. Cohen | Director, Ten Percent Owner | 06 Oct 2020 | 237,149 | 370,024 | - | - | Common Stock | ||
| Marc A. Cohen | Director, Ten Percent Owner | 06 Oct 2020 | 1,482,183 | 1,852,207 | - | - | Common Stock | ||
| Marc A. Cohen | Director, Ten Percent Owner | 06 Oct 2020 | 2,484,425 | 2,484,425 | - | - | Common Stock | ||
| Marc A. Cohen | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 06 Oct 2020 | 5,030 | 5,030 | - | 19 | 95,570 | Common Stock |
| William T. Mckee | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 06 Oct 2020 | 5,263 | 5,263 | - | 19 | 99,997 | Common Stock |
| Kenneth C. Anderson | Director | 06 Oct 2020 | 16,939 | 16,939 | - | - | Common Stock | ||
| Kenneth C. Anderson | Director | 06 Oct 2020 | 142,857 | 0 | - | - | Series B Preferred Stock | ||
| Kenneth C. Anderson | Director | 06 Oct 2020 | 142,857 | 0 | - | - | Series B Preferred Stock | ||
| Kenneth C. Anderson | Director | 06 Oct 2020 | 347,840 | 0 | - | - | Series A Preferred Stock | ||
| Kenneth C. Anderson | Director | 06 Oct 2020 | 347,840 | 0 | - | - | Series A Preferred Stock | ||
| Kenneth C. Anderson | Director | 06 Oct 2020 | 152,160 | 0 | - | - | Series A Preferred Stock | ||
| Kenneth C. Anderson | Director | 06 Oct 2020 | 152,160 | 0 | - | - | Series A Preferred Stock | ||
| Kenneth C. Anderson | Director | 06 Oct 2020 | 16,939 | 16,939 | - | - | Common Stock | ||
| Kenneth C. Anderson | Director | 06 Oct 2020 | 41,244 | 63,543 | - | - | Common Stock | ||
| Kenneth C. Anderson | Director | 06 Oct 2020 | 41,244 | 63,543 | - | - | Common Stock | ||
| Kenneth C. Anderson | Director | 06 Oct 2020 | 18,040 | 45,038 | - | - | Common Stock | ||
| Kenneth C. Anderson | Director | 06 Oct 2020 | 18,040 | 80,376 | - | - | Common Stock | ||
| Elena Prokupets | Director | 06 Oct 2020 | 118,574 | 118,574 | - | - | Common Stock | ||
| Elena Prokupets | Director | 06 Oct 2020 | 1,000,000 | 0 | - | - | Series A Preferred Stock | ||
| Elena Prokupets | Director | 06 Oct 2020 | 5,000,000 | 0 | - | - | Series A Preferred Stock | ||
| Elena Prokupets | Director | 06 Oct 2020 | 592,873 | 592,873 | - | - | Common Stock | ||
| Malcolm Salter | Director | 06 Oct 2020 | 2,823 | 14,679 | - | - | Common Stock | ||
| Malcolm Salter | Director | 06 Oct 2020 | 100,000 | 0 | - | - | Series A Preferred Stock | ||
| Malcolm Salter | Director | 06 Oct 2020 | 23,809 | 0 | - | - | Series B Preferred Stock | ||
| Malcolm Salter | Director | 06 Oct 2020 | 11,856 | 11,856 | - | - | Common Stock | ||
| Malcolm Salter | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 06 Oct 2020 | 1,315 | 15,994 | - | 19 | 24,985 | Common Stock |
| Bruce L. Downey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 17,786 | 17,786 | - | - | Stock Option (Right to Buy) | |
| Alain J. Cohen | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 17,786 | 17,786 | - | - | Stock Option (Right to Buy) | |
| Marc A. Cohen | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 17,786 | 17,786 | - | - | Stock Option (Right to Buy) | |
| Marc A. Cohen | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 725,002 | 725,002 | - | - | Stock Option (Right to Buy) | |
| Andrew Hirsch | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 1,691,672 | 1,691,672 | - | - | Stock Option (Right to Buy) | |
| Kenneth C. Anderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 17,786 | 17,786 | - | - | Stock Option (Right to Buy) | |
| Elena Prokupets | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 17,786 | 17,786 | - | - | Stock Option (Right to Buy) | |
| Malcolm Salter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 17,786 | 17,786 | - | - | Stock Option (Right to Buy) |